taxanes


Also found in: Dictionary.

tax·anes

(taks'ānz),
A class of antitumor agents derived directly or semisynthetically from Taxus brevifolia, the Pacific yew; examples include paclitaxel and docetaxel.

taxanes

Oncology A family of antimitotic/antimicrotubule agents that inhibit cancer cell growth by stopping cell division
References in periodicals archive ?
Tesetaxel has several potential therapeutic advantages over currently available taxanes, including oral administration with a low pill burden, a patient-friendly dosing regimen, and a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions.
Resistance to taxanes may be intrinsic or acquired due to long term exposure to this chemotherapeutic agent.
While no new safety concerns were identified, differences in toxicity profiles among the taxanes were noted.
It is an orally available tubulin targeting agent that has demonstrated efficacy in preclinical studies against hormone sensitive, castration resistant, as well as taxane resistant prostate cancer.
Results: Oral administration of taxane fractions isolated from Taxus chinensis (containing 17.
The taxanes and vinca alkaloids target that part of the cytoskeleton known as microtubules.
Unlike standard taxanes that must be administered intravenously, tesetaxel is a capsule that is taken by mouth.
Chemotherapy: The patients in the study were receiving either platinum or taxane chemotherapy.
In addition to improving the response of some cancer to taxane, our findings add support to emerging evidence that cancer cell metabolism and mitosis functions are coupled," Ahmed Ashour Ahmed, member of the faculty at Oxford University said.
Taxanes are anti-microtubule agents, and it is therefore logical to look at microtubule components for association with sensitivity or resistance to these agents.
GlaxoSmithKline recently announced that the FDA has approved TYKERB[R] (lapatinib), in combination with Xeloda[R] (capecitabine), for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
Under the agreement, EPS has agreed to use its ongoing cell factory and metabolic engineering programs to develop efficient methods for the production of paclitaxel and taxane intermediates used to produce paclitaxel, docetaxel and other semi-synthetic taxanes for pharmaceutical applications.